Search 

Medxense offers accurate continuous glucose monitoring for the intensive care unit (ICU). Normalization of patient blood glucose allows hospitals to reduce mortality and patient length of stay. 

The patented sensor technology platform is the only in the field to offer both high accuracy and near-instantaneous measurements in the hypoglycemic range, necessary for safe normalization of blood glucose.

We are now looking for an investment of 3 MUSD to fund clinical trials in the 2nd half of 2014. Expected exits are trade sale or IPO.

Mendor - the new diabetes movement

Mendor is a diabetes technology company with two main products:
1. Mendor Discreet - a globally unique all-in-one integrated glucose meter
2. Mendor Balance - a cloud-based glucose profiling & diabetes management platform for clinics, HCPs & diabetics.

Our key partners include:
Menarini Diagnostics, Merck Serono, Sanofi & Lilly.

Our revenue history:
2011: 0,2M€
2012: 0,6M€
2013 01-07: 3,2M€

Company presentation with some more details:
https://www.dropbox.com/sh/ycp289w4g8wmqwn/0Yj457jnK8/Mendor_Company_Presentation-Aug_2013.pdf

Evergreen Fund, Investment arm of Merieux Institute Group still owned by Merieux Family.  In the worldwide group several companies like BioMerieux, Merieux Nutraceuticals, Transgene etc.

Movendos Ltd provides innovative web/mobile tools for health & wellness coaching professionals. With our tool coaches can take their own coaching content online, follow customer’s progress, motivate them and measure the effectiveness of coaching in real time.